Pancreatic cancer is a common lethal cancer of the digestive system and one of the malignancies with the poorest prognosis. In the United States, the mortality rate of pancreatic cancer accounted for the 4th of all malignant tumors in 2007. In recent years, the incidence of pancreatic cancer has increased substantially in large and medium-sized cities in China, with the annual incidence rate of about 9/100,000 in Shanghai, Tianjin and other high-incidence areas having increased fourfold in 20 years. Due to the insidious onset of pancreatic cancer, non-specific clinical manifestations and rapid disease progression, most patients are already in advanced stage or have distant metastasis when diagnosed. The 5-year survival rate of advanced pancreatic cancer is less than 5%, and the overall outcome is extremely poor. Surgery is the only treatment for pancreatic cancer patients to achieve long-term survival. Only 10% to 15% of patients have the chance of surgical resection, and the 5-year survival rate after surgery is about 20%. Only about 50% of patients who are evaluated as resectable before surgery eventually undergo radical resection, and the rest of patients often give up radical surgery because of intraoperative metastasis or tumor invasion by large blood vessels. Therefore, non-surgical treatment plays a major role in the comprehensive treatment of pancreatic cancer. Non-surgical treatment of pancreatic cancer includes chemotherapy, radiation therapy, physical therapy, molecular targeted therapy and Chinese herbal medicine. Chemotherapy is the main treatment for advanced pancreatic cancer or metastatic pancreatic cancer. Various chemotherapy regimens, mainly gemcitabine, have been widely used in clinical practice, but chemotherapy can only extend the survival of patients to a limited extent. Some patients have developed resistance to gemcitabine, and there is no uniform second-line chemotherapy regimen. The value of radiotherapy for the treatment of intermediate to advanced pancreatic cancer is still controversial. The findings of several randomized controlled clinical trials have been inconsistent, with differences in the range of irradiation fields, radiotherapy techniques and dose selection being the main reasons for the differences. As a local therapy, radiotherapy is not recommended in patients with pancreatic cancer with metastasis because it is difficult to control the metastasis of the tumor. The use of physical therapy, such as high-intensity focused ultrasound knife in pancreatic cancer, is still in clinical trials worldwide, and its efficacy remains to be observed and evaluated. In recent years, molecularly targeted drugs have shown promising applications in the treatment of malignant tumors. Erlotinib (Troche) is currently the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) approved by the US FDA for use in pancreatic cancer patients, but it only improves the median survival from 5.9 months to 6.4 months and 1-year survival from 17% to 24% in advanced pancreatic cancer. Cetuximab and bevacizumab demonstrated higher efficiency and 1-year survival than gemcitabine alone by combining with gemcitabine in a prior phase I/II clinical trial. However, their efficacy has not been confirmed in subsequent phase III clinical trials with large samples. In recent years, Chinese medicine has shown some advantages in the comprehensive treatment of tumors. 2010, PANCREAS, an American journal of pancreatology, published an academic paper “Multidisciplinary comprehensive treatment model of pancreatic cancer liver metastases based on chemotherapy, radiotherapy and/or Chinese herbal medicine treatment” written by Dr. Ouyang Huaqiang from Cancer Hospital of Tianjin Medical University, which, after a multifactorial analysis of 164 patients with pancreatic cancer liver metastases, pointed out that analysis of 164 patients with pancreatic cancer liver metastases, it was pointed out that chemotherapy and herbal treatment to clear heat and dampness were prognostic protective factors for patients with pancreatic cancer liver metastases, and that a multidisciplinary integrated treatment model based on the combination of chemotherapy, radiotherapy and herbal treatment could benefit patients. The authors also established a prognostic index model for liver metastases from pancreatic cancer, which can be used to estimate the overall survival time of patients and provide a basis for selecting the appropriate combination treatment model. The results of the phase I clinical trial of “Huachansu for the treatment of hepatocellular liver cancer, non-small cell lung cancer and pancreatic cancer” showed that the Chinese medicinal preparation Huachansu was safe and effective in the treatment of advanced pancreatic cancer, with some patients achieving tumor shrinkage or stabilization. The subsequent phase II clinical study of the project is underway. In summary, pancreatic cancer remains one of the most poorly prognosed cancers at present. Most patients still lack effective treatment due to the loss of surgical opportunities. The improvement of the overall survival rate of advanced pancreatic cancer needs to rely on a multidisciplinary and comprehensive treatment model, especially the integrated use of Chinese and Western medical treatment methods.